2024-02-15 23:55:27 ET
10x Genomics, Inc. (TXG)
Q4 2023 Results Earnings Conference Call
February 15, 2024, 04:30 PM ET
Company Participants
Cassie Corneau - Director, Investor Relations and Strategic Finance
Serge Saxonov - Chief Executive Officer and Co-Founder
Justin McAnear - Chief Financial Officer
Conference Call Participants
Dan Brennan - TD Cowen
Daniel Arias - Stifel Financial
Kyle Mikson - Canaccord Genuity
Patrick Donnelly - Citigroup
Subbu Nambi - Guggenheim Partners
Tejas Savant - Morgan Stanley
Michael Ryskin - Bank of America
Matthew Sykes - Goldman Sachs
Mason Carrico - Stephens, Inc.
Presentation
Operator
Good afternoon. My name is Jeannie, and I will be your conference operator today. I would like to welcome you to the 10x Genomics Fourth Quarter And Full-Year 2023 Earnings Conference Call. All lines have been placed in mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you.
I would now like to turn our call over to Cassie Corneau. You may begin your conference.
Cassie Corneau
Thank you. And good afternoon, everyone. Earlier today, 10x Genomics released financial results for the fourth quarter and full year ended December 31, 2023. If you have not received this news release, or if you would like to be added to the company's distribution list, please send an email to investors@10xgenomics.com.
An archived webcast of this call will be available on the investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call.
Before we begin, I'd like to remind you that management will make statements during this call that are forward looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release 10x Genomics issued today and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission.
10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.
Joining the call today are Serge Saxonov, our CEO and Co-Founder, and Justin McAnear, our Chief Financial Officer. We will host a question-and-answer session after our prepared remarks. We ask analysts to please keep to one question so that we may accommodate everyone in the queue.
Last week, we were a Silver Sponsor of the 2024 Advances in Genome Biology and Technology General Meeting, known as AGBT. During our workshop, our team presented exciting science and details of our upcoming product launches. While Serge will highlight some of these today, we encourage you to check out the presentation replay on our website if you didn't see the news or if you would like more information. ...
Read the full article on Seeking Alpha
For further details see:
10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript